World Congress at ACG2017
Symposium 1A: Hepatocellular Carcinoma
Category: Liver
David Bernstein, MD, FACG
Professor of Medicine
Hofstra Northwell School of Medicine
Manhasset, NY, US
Kelly Burak, MD, FRCPC, MSc (Epid)
Professor, Departments of Medicine and Oncology; Associate Dean, Continuing Medical Education & Professional Development
University of Calgary
Calgary, Alberta, Canada
Professor of Medicine
Hofstra Northwell School of Medicine
Manhasset, NY, US
David Bernstein, MD, FACG, is the VIce Chair of Medicine for Clinical Trials, Chief of Hepatology and Director of the Sandra Atlas Bass Center for Liver Diseases at Northwell Health. He is Professor of Medicine at the Hofstra Northwell School of Medicine. He graduated from Johns Hopkins University and received his MD from SUNY Stony Brook School of Medicine. He completed his training in Gastroenterology and Hepatology at the University of Miami/Jackson Memorial Hospital in Miami, FL, under the direction of Dr. Eugene Schiff. Dr. Bernstein has participated in more than 200 large clinical and investigator-initiated research trials.
Symposium 1A: Hepatocellular Carcinoma
Monday, October 16
11:30 AM – 12:45 PM
Professor, Departments of Medicine and Oncology; Associate Dean, Continuing Medical Education & Professional Development
University of Calgary
Calgary, Alberta, Canada
Dr. Burak is Professor of Medicine at the University of Calgary where he is currently the Associate Dean of Continuing Medical Education and Professional Development. His clinical and research interests include hepatocellular carcinoma (HCC) and liver transplantation. He serves as the Director of Southern Alberta Liver Transplant Clinic and is cross-appointed to the Department of Oncology. He has served as the local principal investigator in several pivotal randomized clinical trials evaluating therapies for intermediate and advanced HCC. Dr. Burak has been involved in updating provincial and national guidelines for the management HCC. He organized the Canadian Association for the Study of the Liver (CASL) HCC meeting and was the lead author of the meeting proceedings. He was a Steering Committee member for the Canadian Liver Listing and Allocation Conference, which lead to Canada adopting total tumour volume (TTV) and alphafetoprotein (AFP) criteria for transplantation of HCC. Dr. Burak is actively involved in Medical Education and spoken on the management of HCC in Canada, USA, Korea and Australia.
Symposium C: Updates in Liver Disease
Saturday, October 14
3:45 PM – 5:00 PM
Diagnosis and Multi-modality Management of Hepatocellular Carcinoma
Saturday, October 14
4:05 PM – 4:25 PM
Symposium 1A: Hepatocellular Carcinoma
Monday, October 16
11:30 AM – 12:45 PM
Simultaneous Plenary Session 1A: Liver
Monday, October 16
4:30 PM – 5:00 PM
The asset you are trying to access is locked. Please enter your access key to unlock.